Factsheet
Covid-19 (novel coronavirus disease)
Rules for coverage of the costs of testing for SARS-CoV-2 and of associated medical care

Date: 25 June 2020

1. Background

1.1. Revised FOPH testing strategy of 24 June 2020

On the basis of the revised FOPH testing strategy, the Confederation will now cover the costs of outpatient molecular biological and serological analysis for SARS-CoV-2, and of associated medical care, in individuals meeting the FOPH suspected case, testing and reporting criteria of 24 June 2020.

Molecular biological analysis, which makes it possible to obtain a diagnosis in cases of symptoms compatible with Covid-19, is recommended for:

- symptomatic individuals meeting one of the clinical criteria (including rare symptoms) specified in the FOPH testing strategy of 24 June 2020;

- asymptomatic individuals who have been notified by the SwissCovid app of contact with a Covid-19 case (see Fig. 1).

Close contacts of a Covid-19 case who are asymptomatic and in quarantine may also be tested (by PCR and/or serological analysis). The indication for testing is established by the competent cantonal authority (the Cantonal Medical Officer or a contact tracing service acting on his/her behalf).\(^3\) Cantonal Medical Officers may still, in justified cases differing from those specified above, order the testing of asymptomatic individuals (by PCR and/or serological analysis) so as to investigate and control the spread of the virus when outbreaks occur. The costs of molecular biological analysis in such cases will be covered by the

---

\(^{1}\) Available in French / German / Italian at: www.bag.admin.ch/bag/de/home/krankheiten/infektionskrankheiten-bekaempfen/meldesysteme-infektionskrankheiten/meldepflichtige-ik/meldeformulare.html

\(^{2}\) The FOPH suspected case, testing and reporting criteria of 24 June 2020 are available in French / German / Italian at: www.bag.admin.ch/bag/de/home/krankheiten/infektionskrankheiten-bekaempfen/meldesysteme-infektionskrankheiten/meldepflichtige-ik/meldeformulare.html

\(^{3}\) In certain situations, testing of asymptomatic / presymptomatic contacts is indicated (from the 5th day after contact) so that chains of transmission can be broken more rapidly if test results are positive. A negative test does not mean that quarantine can be terminated prematurely!

Further information:
This publication is also available in French, German and Italian.
Confederation. The costs of serological analysis will only be covered by the Confederation if they are explicitly ordered by the Cantonal Medical Officer.

The present rules for the coverage of costs concern outpatient testing for SARS-CoV-2. Inpatient testing is included in inpatient fee-per-case payments (DRG, Art. 49 Health Insurance Act / HIA; SR 832.10); as a result, it does not give rise to any additional costs for patients.

1.2. Clinical criteria for diagnostic testing for SARS-CoV-2

The FOPH recommends diagnostic analysis for SARS-CoV-2 for anyone meeting one of the following clinical criteria specified in the FOPH testing strategy of 24 June 2020:

- symptoms of acute respiratory disease (e.g. coughing, sore throat, shortness of breath, chest pain) and / or
- fever without other etiology and / or
- sudden loss of the sense of smell and / or taste and / or
- in elderly individuals, acute confusion or deterioration in general health without other etiology

N.B. Other less common and unspecific symptoms may also be associated with Covid-19.

1.3. Laboratory analyses and associated medical care

The Confederation will generally cover the costs of laboratory analysis and the costs of associated medical care. The Confederation will provide a flat rate payment of CHF 50 per test to cover the costs of the associated medical consultation or the corresponding expenses at a test centre (each consultation is conducted by a medical practitioner on site, who checks the indication in each case). Included in the flat rate payment are the costs for the medical consultation, swab, protective materials and communication of the test results. The materials required for the swab are made available by the laboratory and covered by the order charge.

The Confederation will cover CHF 119 for the molecular biological analysis for SARS-CoV-2 in accordance with Article 26 paragraph 2 of COVID-19 Ordinance 3. This sum is made up as follows: CHF 95 for the test and CHF 24 for order processing, overhead costs and sampling materials.

The Confederation will cover CHF 63 for the serological test for SARS-CoV-2 in accordance with Article 26 paragraph 3 of COVID-19 Ordinance 3. This sum is made up as follows: CHF 39 for the test and CHF 24 for order processing, overhead costs and sampling materials. If additional analyses are requested in the same order, the laboratory fee of CHF 24 must not be charged again to the compulsory health insurance scheme.

What is generally covered by the Confederation are maximum amounts, which means that lower costs may, or must, also be invoiced – for example, in cases where a service provider has benefited from direct or indirect price reductions (cf. Art. 56 para. 3–4 HIA).

1.4. Conditions for coverage of costs by the Confederation

1.4.1. Service providers

Service providers must meet the requirements for admission specified in the HIA. In the case of test centres or drive-in facilities, the costs will only be covered by the Confederation if these establishments are operated by or on behalf of the canton. With regard to quality assurance, such test centres or drive-in facilities should, at a minimum, meet the relevant cantonal requirements. Services provided by privately organised test centres or drive-in facilities which are not commissioned by the canton will not, therefore, be covered by the Confederation.

1 Aching muscles, headache, general weakness, head cold, gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea, stomach ache), skin rashes (e.g. pseudo-frostbite, urticarial, vesicular or morbilliform rashes)

Further information:
Federal Office of Public Health, Health and Accident Insurance Directorate, leistungen-krankenversicherung@bag.admin.ch,
www.bag.admin.ch
This publication is also available in French, German and Italian.
Analysis for SARS-CoV-2 must be ordered by a medical practitioner.

1.4.2. Sampling

The service provider, as specified in the HIA, or the test centre operated by or on behalf of the canton, doing the sampling and is also responsible for completion of the laboratory order with the patient's personal details (including health insurance details), clinical information and the indication for the analysis. Responsibility for assessing compliance with the requirements for the coverage of test costs rests with a medical practitioner.
Overview: Coverage of analyses for SARS-CoV-2

At least one of the requirements specified in the FOPH testing strategy of 24 June 2020 is met:

- **a.** symptomatic individuals meeting one of the clinical criteria in the FOPH testing strategy of 24 June 2020
- **b.** asymptomatic individuals who have been notified by the SwissCovid app of contact with a COVID-19 case
- **c.** close contacts of a Covid-19 case who are asymptomatic and in quarantine, may also be tested; the indication for testing is established by the competent cantonal authority.
- **d.** Cantonal Medical Officers may decide to have asymptomatic individuals tested if this is justified to investigate and control an outbreak.

### Requirements of the FOPH testing strategy of 24 June 2020 not met

- **Requested by employer**
- **Requested by person concerned**

### Analysis done by the laboratory: the laboratories must address the invoices according to the specification on the laboratory order

- Invoice submitted to insurer*
- Invoice submitted to employer
- Invoice submitted to patient

### Confederation

The costs of the laboratory analysis and associated services are fully borne by the Confederation

### Employer

Costs are fully borne by the employer

### Patient

Costs are fully borne by the patient

* Patients must be informed by the medical practitioner of any additional costs arising for which they are liable.

Further information:

Federal Office of Public Health, Health and Accident Insurance Directorate, leistungen-krankenversicherung@bag.admin.ch.
www.bag.admin.ch
This publication is also available in French, German and Italian.
2. Technical procedure

2.1. Invoicing

The service providers submit the invoice, specifying the ZSR number / GLN number, to the insurer responsible (health insurer, Military Insurance), or to the Common Institution. The individual cost components – for sampling and the laboratory analysis – are to be itemised on the invoice and invoiced separately by the service provider concerned. The insurer responsible is the provider of coverage against illness for the person tested. For those not insured in Switzerland, the Common Institution under Article 18 of the HIA is responsible.

Invoices are to be submitted in a standardised form, as specified in Article 26a paragraph 1 of COVID-19 Ordinance 3, including the administrative and medical information specified in Article 59 of the Health Insurance Ordinance (HIO, SR 832.102), to the insurer responsible, or to the Common Institution, under the tiers payant system, in accordance with Article 42 paragraph 2 HIA. The insurer, or the Common Institution, communicates the number of medical and laboratory standard charges financed in advance and the number of insured persons, and submits invoices quarterly to the Confederation. The person tested is not liable for any co-payment for medical care in accordance with Article 26 paragraph 6 of COVID-19 Ordinance 3⁵.

For additional investigations or medical care which are not required for SARS-CoV-2 sampling and which are performed during or as a result of the coronavirus consultation (e.g. treatment for Covid-19), the act applicable in each case (HIA; AIA, SR 832.20; MIA, SR 833.1) is to be applied. Medical practitioners must inform the person concerned of any costs arising which are not covered by the Confederation’s flat rate coverage, and which thus give rise to additional costs (e.g. co-payment) for the patient. Such services are to be invoiced separately from the analysis by the service provider, in accordance with the applicable provisions in the relevant federal act.

Invoices are generally to be submitted electronically (applicable standard: General Invoice Request of the Data Exchange Forum).

While COVID-19 Ordinance 3 is in force (until 13 September 2020), item no. 3186.00 of Annex 3 to the Health Insurance Benefits Ordinance⁶ must not be applied for testing for SARS-CoV-2 in connection with Article 26a paragraph 2.

2.2. Tariffs and tariff numbers to be used by service providers

The following tariffs and tariff numbers may only be used for tests carried out in accordance with the FOPH testing strategy (Section 1.1).

- Invoicing of the medical flat rate / sampling in accordance with Article 26 paragraphs 2 and 3 of COVID-19 Ordinance 3, specifying:
  - For medical practices
    - Tariff: 406
    - Tariff no.: 3028
    - Designation: “Medical flat rate for SARS-CoV-2 test in accordance with FOPH testing strategy – flat rate for medical practitioners”
    - Price: CHF 50.00 (in accordance with Art. 26 para. 2 and 3 of COVID-19 Ordinance 3)
    - Chargeable no more than once per calendar day
  - For hospitals
    - Tariff: 003
    - Tariff no.: 99.9010.00.31

⁵ Art. 26 para. 6 COVID-19 Ordinance 3
⁶ KLV, SR 832.112.31

Further information:
Federal Office of Public Health, Health and Accident Insurance Directorate, leistungen-krankenversicherung@bag.admin.ch.
www.bag.admin.ch
This publication is also available in French, German and Italian.
Designation: “Medical flat rate for SARS-CoV-2 test in accordance with FOPH testing strategy – flat rate for hospitals”
- Price: CHF 50.00 (in accordance with Art. 26 para. 2 and 3 of COVID-19 Ordinance 3)
- Chargeable no more than once per calendar day

Invoicing of the molecular biological analysis for SARS-CoV-2 in accordance with Article 26 paragraph 2 of COVID-19 Ordinance 3, specifying:
- Tariff: 350
- Tariff no.: 99.9020.01.31
- Designation: “Laboratory molecular biological SARS-CoV-2 test in accordance with FOPH testing strategy – flat rate”
- Price: CHF 119.00 (in accordance with Art. 26 para. 2 of COVID-19 Ordinance 3)
- Chargeable no more than once per calendar day

Invoicing of the serological analysis for SARS-CoV-2 in accordance with Article 26 paragraph 3 of COVID-19 Ordinance 3, specifying:
- Tariff: 350
- Tariff no.: 99.9021.01.31
- Designation: “Laboratory serological SARS-CoV-2 test in accordance with FOPH testing strategy – flat rate”
- Price: CHF 63.00 (in accordance with Art. 26 para. 3 of COVID-19 Ordinance 3)
- Chargeable no more than once per calendar day

2.3. Invoice control

Insurers and the Common Institution check invoices for the following points:
- Compliance level of flat rates (amounts specified in Art. 26 para. 2 and 3 of COVID-19 Ordinance 3)
- Entitlement of service provider to submit invoices (based on the ZSR number or GLN number, cf. Art. 26 para. 4 of COVID-19 Ordinance 3)
- no items other than the flat rate envisaged are included in the invoice
- the same analysis has not been charged for more than once per day

If the legal requirements for invoicing are not fulfilled, the invoice is to be returned to the service provider as specified in the HIA, and not settled. The service provider as specified in the HIA must then rectify and resubmit the invoice.

2.4. Reporting to the FOPH

Insurers or the Common Institution report quarterly to the FOPH the number of analyses which they have covered to service providers, and the amount covered, at the beginning of January, April, July and October, with the first report being submitted at the beginning of October 2020 (cf. Art. 26a para. 5 COVID-19 Ordinance 3). Each report should include details of the number of cases in the previous quarter.

3. Entry into force